Otonomy Announces OTIPRIO® Co-Promotion Agreement with Glenmark Therapeutics for Acute Otitis Externa Indication
02. Mai 2019 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, May 02, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the...
Otonomy to Participate in SunTrust Robinson Humphrey Life Sciences Summit
01. Mai 2019 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, May 01, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced...
Otonomy Reports Third Quarter 2017 Financial Results and Provides Corporate Update
08. November 2017 16:12 ET
|
Otonomy, Inc.
SAN DIEGO, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy Reports Positive Results from AVERTS-2 Phase 3 Trial of OTIVIDEX™ in Patients with Ménière's Disease
08. November 2017 16:05 ET
|
Otonomy, Inc.
Achieved primary endpoint (p value = 0.029)Company plans to meet with FDA to discuss results and clinical requirements for registrationManagement will review results during third quarter conference...
Otonomy to Report Third Quarter 2017 Financial Results and Provide Corporate Update
01. November 2017 16:05 ET
|
Otonomy, Inc.
SAN DIEGO, Nov. 01, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy Provides Business and Financial Update
13. September 2017 07:30 ET
|
Otonomy, Inc.
Actions taken to reduce costs following suspension of OTIVIDEX™ developmentNon-commercial workforce reduced by one-thirdCurrent cash balance expected to fund company into 2020Review underway to...
Otonomy Reports First Quarter 2017 Financial Results and Provides Corporate Update
04. Mai 2017 16:27 ET
|
Otonomy, Inc.
SAN DIEGO, May 04, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy to Report Fourth Quarter and Full Year 2016 Financial Results and Provide Corporate Update
24. Februar 2017 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, Feb. 24, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
Otonomy Holds Investor and Analyst Day and Provides Corporate Update
07. Oktober 2016 08:00 ET
|
Otonomy, Inc.
SAN DIEGO, Oct. 07, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy Successfully Completes One-Year, Multiple-Dose Clinical Safety Trial for OTO-104 in Ménière’s Disease Patients
01. August 2016 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, Aug. 01, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...